To assess the benefits and harms of 3,4-DAP for autoimmune MG, transient NMG and the CMS on 1) endurance, and 2) muscle strength, quality of life and Myasthenia Gravis Foundation of America (MGFA) status.
We are collecting information on visitors to our website to ensure Cochrane resources meet the needs of our users. Your data will be anonymised for processing, will be stored securely, and will not be shared with any third parties.